Valerie Vanhooren

Company: ONA Therapeutics

Job title: Co-Founder & Chief Executive Officer

Bio:

Valerie is co-founder and CEO of Ona Therapeutics. Since 2019 she has guided the growth and development of Ona’s pipeline of first-in-class in ADCs and antibodies and secured over 35 million euros from a syndicate of international investors and non-dilutive grants. Prior to Ona she held leading R&D roles at SpliceBio and Ablynx (acquired by Sanofi), where she led drug development collaborative partnerships.

Seminars:

Opportunity to be First-in-Class: Considerations for Collaborations with New Targets 11:10 am

What are the economics of having a new target for others to develop an ADC around? Discussing opportunities to be first-in-class pursuing underexploited targets  Debating the decision to leverage the best linker-payload platform or off-patent technologies, considering the influence on the side effect profileRead more

day: Conference Day Two